Technical Analysis: 11 January 2019 By Violeta Todorova 11 January 2019, 8:45 AM Rio Tinto, Magellan Financial Group, Corporate Travel Management and New Hope Corporation Read more...
Technical Analysis: 10 January 2019 By Violeta Todorova 10 January 2019, 2:00 PM Fortescue Metals, Treasury Wine Estate, Crown Resorts and Pendal Group Read more...
Magellan Financial Group: Solid FUM performance By Scott Murdoch 09 January 2019, 1:47 PM Performing through the volatility Read more...
Woodside Petroleum By Adrian Prendergast 09 January 2019, 10:32 AM Oil volatility uncovers value Read more...
Volpara Health Technologies By Scott Power 09 January 2019, 9:12 AM ScreenPoint partnership a positive Read more...
Technical Analysis: 7 January 2019 By Violeta Todorova 07 January 2019, 8:23 AM JB Hi Fi, RedMed, CSL and NEXTDC Read more...
Technical Analysis: 4 January 2019 By Violeta Todorova 04 January 2019, 10:06 AM Northern Star, Perseus Mining. Livehire and Smart Group Read more...
Technical Analysis: 3 January 2019 By Violeta Todorova 03 January 2019, 10:00 AM Lovisa, OceanaGold, Regis Resources and Atlas Arteria. Read more...
An Update on COVID-19 Vaccine Development By Raymond Chan 24 April 2020, 12:00 AM 新冠肺炎疫苗真可快將面世？ 世界各地法寶盡出，奮力對抗新型冠狀病毒肺炎這個共同「敵人」，可惜迄今為止只能拖慢疫情擴散的速度，顯得治標不治本。其實，大家都明白到，若要成功戰勝新冠肺炎，唯一最有效的方法就是成功研發出疫苗。 很大程度上要感謝中國，在疫情初期就分享了新冠肺炎病毒的基因排序，目前已經有至少60種候選新冠肺炎疫苗，正在經由多間藥廠、生物科技公司和研究機構進行試驗 抗疫最強「武器」 臨床試驗階段 目前為止，美國生物科技公司 Moderna Therapeutics 所研發的疫苗 mRNA-1273，是最讓各方人士期盼的抗疫最強「武器」。此疫苗已經在美國華盛頓州進行臨床試驗，用於此次疫情中的高危群體，例如是前線醫護人員 澳洲的科研人員也不甘後人，現正加快進行大規模的人體測試，觀察過去幾十年以來一直用於治療肺結核病的現成疫苗，能否有效地保護前線醫護人員免受新冠肺炎感染。臨床測試中的新冠肺炎疫苗 Bacillus Calmette-Guerin（簡稱BCG），將會用於分布在澳洲全國各地的4,000位醫院前線醫護人員，務求從中了解此疫苗能否有效地紓緩新冠肺炎的病徵 BCG疫苗原本是用於對付... Read more...
Zip Co: AGM and capital raising By Richard Coles 03 December 2019, 12:00 AM Zip Co (ASX:Z1P) has announced a A$60m capital raising in conjunction with its AGM. While we are supportive of Z1P's growth plans, the current capital raising does add to significant dilution throughout CY19 which needs to be justified by execution. Read more...